Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Magnesium hydroxide is an antacid that neutralizes gastric acid, increasing gastric p H. Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of acid secretion. Sodium bicarbonate is a systemic antacid that neutralizes gastric acid and also provides alkalinization of urine.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of frequent heartburn (FDA-approved for over-the-counter use),Gastroesophageal reflux disease (GERD),Erosive esophagitis,Duodenal ulcer,Gastric ulcer,Zollinger-Ellison syndrome,Helicobacter pylori eradication (as part of combination therapy)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
One tablet (containing 400 mg magnesium hydroxide, 20 mg omeprazole, 1000 mg sodium bicarbonate) orally once daily, taken at least 1 hour before a meal.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Magnesium hydroxide: not applicable (local action); omeprazole: 0.5-1 hour (terminal); sodium bicarbonate: not applicable (buffering agent). Omeprazole's half-life is short but pharmacodynamic effect (acid suppression) lasts ~24 hours due to covalent binding to proton pumps.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Omeprazole is extensively metabolized in the liver via CYP2C19 and CYP3A4; its metabolites are inactive. Magnesium hydroxide and sodium bicarbonate are not metabolized; they act locally and are partially absorbed. Sodium bicarbonate is converted to carbon dioxide and water via carbonic anhydrase.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Magnesium hydroxide: primarily fecal (unabsorbed magnesium), renal (absorbed magnesium); omeprazole: renal (~77% as metabolites) and fecal (~23%); sodium bicarbonate: renal (as bicarbonate or CO2).
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Magnesium hydroxide: negligible; omeprazole: 95% (albumin and alpha1-acid glycoprotein); sodium bicarbonate: negligible.
55–65% bound to plasma proteins, primarily albumin.
Magnesium hydroxide: not applicable (local); omeprazole: 0.3-0.5 L/kg (extensive tissue distribution); sodium bicarbonate: 0.5-1 L/kg (total body water).
0.4–0.6 L/kg, indicating distribution into total body water.
Magnesium hydroxide: not absorbed orally; omeprazole: 30-40% (oral, delayed-release formulation); sodium bicarbonate: 100% (oral, completely absorbed).
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of magnesium accumulation and sodium overload. For e GFR 30-59 m L/min/1.73m², reduce dose to one tablet every other day and monitor serum magnesium and sodium.
No dose adjustment required for renal impairment.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce omeprazole dose to 10 mg (not available in this combination) or consider alternative; use with caution. Child-Pugh C: Contraindicated due to omeprazole accumulation.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Not recommended for use in pediatric patients (safety and efficacy not established).
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Use with caution due to increased risk of electrolyte imbalance (hypermagnesemia, metabolic alkalosis) and renal impairment. Consider reducing dose to one tablet every other day. Monitor renal function and serum electrolytes.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None
No FDA black box warning exists for this drug.
Long-term use (≥1 year) may increase risk of osteoporosis-related fractures; hypomagnesemia with prolonged PPI use; cyanocobalamin (vitamin B12) deficiency with long-term acid suppression; magnesium hydroxide may cause diarrhea; sodium bicarbonate may cause metabolic alkalosis, fluid retention, and worsen hypertension or heart failure; acute interstitial nephritis reported with PPIs; monitor renal function; interaction with clopidogrel (omeprazole reduces clopidogrel's active metabolite); increased risk of Clostridium difficile infection; avoid concurrent use of atazanavir or nelfinavir.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to any component; Concurrent use of rilpivirine-containing products; Severe renal impairment (Cr Cl <30 m L/min) due to risk of magnesium toxicity; Sodium-restricted diet (due to sodium content); Patients with metabolic alkalosis; Children under 12 years for over-the-counter use (varies by product).
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Take on empty stomach; food reduces omeprazole absorption. Avoid high-fat meals. No known specific food interactions with antacid components.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
First trimester: No evidence of teratogenicity from omeprazole or magnesium hydroxide; sodium bicarbonate may cause metabolic alkalosis. Second and third trimesters: Omeprazole is considered low risk; magnesium hydroxide can cause hypotonia and respiratory depression in neonates with prolonged use; sodium bicarbonate may lead to fluid overload or alkalosis.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Omeprazole is excreted in breast milk in low amounts (M/P ratio ~0.5); magnesium hydroxide and sodium bicarbonate are poorly absorbed; considered compatible with breastfeeding, but monitor infant for diarrhea or electrolyte imbalance.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No dose adjustment typically required; monitor for magnesium toxicity in renal impairment; consider reduced omeprazole dose if CYP2C19 polymorphisms present; sodium bicarbonate dose should be adjusted to avoid metabolic alkalosis.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
This combination uses sodium bicarbonate to rapidly raise gastric p H, enabling omeprazole absorption (enteric-coated omeprazole may be prematurely released; use non-enteric formulations). Magnesium hydroxide provides additional acid neutralization and a laxative effect. Avoid in patients with renal impairment (risk of magnesium toxicity, sodium overload). Administer on an empty stomach at least 1 hour before meals. Do not split or crush tablets.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take this medication on an empty stomach at least 1 hour before a meal.,Swallow the tablet whole; do not crush or chew it.,Do not take with other antacids or calcium supplements.,Notify your doctor if you have kidney disease or are on a low-sodium diet.,Common side effects include diarrhea or stomach pain; report severe or persistent symptoms.,Avoid alcohol and NSAIDs as they can worsen stomach irritation.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
"Niclosamide may inhibit the cytochrome P450 enzyme CYP2C19, which is the primary hepatic enzyme responsible for the metabolism of omeprazole. This inhibition can lead to decreased clearance and elevated plasma concentrations of omeprazole, potentially increasing its therapeutic and adverse effects. Clinically, this could result in enhanced acid suppression and an increased risk of omeprazole-related side effects such as headache, diarrhea, or vitamin B12 deficiency with prolonged use."
"Cyclosporine, a potent immunosuppressant and P-glycoprotein inhibitor, can significantly increase the systemic exposure of omeprazole by inhibiting its efflux transport and potentially its metabolism via CYP3A4 and CYP2C19. This interaction may lead to elevated omeprazole serum concentrations, increasing the risk of adverse effects such as headache, diarrhea, and vitamin B12 deficiency with long-term use. Clinicians should be vigilant for signs of omeprazole toxicity when coadministered with cyclosporine."
"Omeprazole, a proton pump inhibitor (PPI), is primarily metabolized by cytochrome P450 (CYP)2C19 and, to a lesser extent, CYP3A4. Stiripentol, an antiepileptic drug, is a potent inhibitor of CYP2C19 and CYP3A4. Coadministration may lead to a significant increase in omeprazole exposure (AUC up to 5-fold), potentially increasing the risk of adverse effects such as hypomagnesemia, Clostridioides difficile infection, or bone fracture. Conversely, stiripentol levels are not expected to be significantly affected, as omeprazole does not inhibit its metabolism."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE vs AEROLATE SR, answered by our medical review team.
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is a Alkalinizing Agent that works by Magnesium hydroxide is an antacid that neutralizes gastric acid, increasing gastric p H. Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of acid secretion. Sodium bicarbonate is a systemic antacid that neutralizes gastric acid and also provides alkalinization of urine.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE and AEROLATE SR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is: One tablet (containing 400 mg magnesium hydroxide, 20 mg omeprazole, 1000 mg sodium bicarbonate) orally once daily, taken at least 1 hour before a meal.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is classified as Category A/B. First trimester: No evidence of teratogenicity from omeprazole or magnesium hydroxide; sodium bicarbonate may cause metabolic alkalosis. Second and third trimesters: Omeprazole is . AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.